Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P30CA043703 | U.S. NIH Grant/Contract | View source | |
| CASE12806 | Other Identifier | Case Comprehensive Cancer Center | |
| NCI-2010-01064 | Other Identifier | NCI/CTRP |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.
PURPOSE: This phase I/II trial studies the side effects and best dose of giving stereotactic radiosurgery and to see how well it works in treating patients with kidney tumors who are poor candidates for surgery.
OBJECTIVES:
Primary
Secondary
Serum Blood Marker Objective:
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
Patients undergo placement of 2-3 fiducial markers in or near the renal tumor. Patients then undergo 4 fractions of stereotactic radiosurgery in the absence of disease progression or unacceptable toxicity. Treatment may repeat at 6 months if tumor is still present.
After radio-surgery, follow-up will be done at 1 , 3 and 6 months and then every 6 months post radiosurgery for a total of 36 months.
PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Series 1: Stereotactic radiosurgery | Experimental | Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy. |
|
| Series 2: Stereotactic radiosurgery | Experimental | Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| stereotactic radiosurgery | Radiation | Series I: Radiation will be delivered in 4 fractions. Series II: Radiation will be delivered in 3 fractions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Tolerated Dose of Radiosurgery | Dose escalation stops if 2/4 (50%) or 3/8 (37.5%) of participants experience DLTs in a given dose level cohort. The maximum tolerated dose will be one dose level below which the DLTs were exceeded. | once every 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival | Radiographic efficacy as measured by overall (percent of participants still alive after study completion) | at 36 months from start of therapy |
| Progression-free Survival | Percent of participants still alive and without tumor progression at study completion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mitchell Machtay, MD | University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland | Ohio | 44106-5065 | United States |
Not provided
Participants were recruited local hospital from 2/2007 to 5/2017.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Series 1/Dose Level 1: Stereotactic Radiosurgery | Dose Level I: Radiation will be delivered in 4 fractions: 6 Gy x 4 fractions: Total of 24 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of b |
| FG001 | Series 1/Dose Level 2: Stereotactic Radiosurgery | Dose Level 2: Radiation will be delivered in 4 fractions: 8 Gy x 4 fractions: Total of 32 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of b |
| FG002 | Series 1/Dose Level 3: Stereotactic Radiosurgery | Dose Level 3: Radiation will be delivered in 4 fractions: 10 Gy x 4 fractions: Total of 40 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of b |
| FG003 | Series 1/Dose Level 4: Stereotactic Radiosurgery | Dose Level 4: Radiation will be delivered in 4 fractions: 12 Gy x 4 fractions: Total of 48 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of b |
| FG004 | Series 2/Dose Level 1: Stereotactic Radiosurgery | Dose Level I: Radiation will be delivered in 3 fractions: 16 Gy X 3 fractions: Total of 48 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of b |
| FG005 | Series 2/Dose Level 2: Stereotactic Radiosurgery | Dose Level 2: Radiation will be delivered in 3 fractions: 18 Gy x 3 fractions: Total of 54 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of b |
| FG006 | Series 2/Dose Level 3: Stereotactic Radiosurgery | Dose Level 3: Radiation will be delivered in 3 fractions: 20 Gy x 3 fractions: Total of 60 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of b |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
All participants who went on treatment.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Series 1/Dose Level 1: Stereotactic Radiosurgery | Series I: Radiation will be delivered in 4 fractions: 6 Gy x 4 fractions total dose of 24 Gy. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Maximum Tolerated Dose of Radiosurgery | Dose escalation stops if 2/4 (50%) or 3/8 (37.5%) of participants experience DLTs in a given dose level cohort. The maximum tolerated dose will be one dose level below which the DLTs were exceeded. | All participants who received treatment. | Posted | Number | Gy | once every 4 weeks |
|
Adverse events were collected over a ten year time period from study activation to study completion. AEs were collected over a 3 year time period for each participant while on study.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Series 1/Dose Level 1: Stereotactic Radiosurgery | Dose Level I: Radiation will be delivered in 4 fractions: 6 Gy x 4 fractions: Total of 24 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| junctional rhythm | Cardiac disorders | CTCAE (3.0) | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hypertension | Vascular disorders | CTCAE (3.0) | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Mitchell Machtay MD | University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | 216-844-2530 | mitchell.machtay@uhhospitals.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 24, 2017 | Feb 11, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D007680 | Kidney Neoplasms |
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D016634 | Radiosurgery |
| ID | Term |
|---|---|
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
| D013238 | Stereotaxic Techniques |
| D019635 | Neurosurgical Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Renal Biopsy | Procedure | At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. |
|
| Serum Blood Markers | Procedure | ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
|
| at 36 months from start of therapy |
| Freedom From Local Progression | Radiographic efficacy as measured as measured by freedom from local progression (percent of participants without local progression or local recurrence after study completion) | at 36 months from start of therapy |
| Freedom to Distant Recurrence | Radiographic efficacy as measured by distant recurrance (percent of participants without distant failure after study completion) | at 36 months from start of therapy |
| UH-Chagrin Highlands | Orange | Ohio | 44122 | United States |
| UH-Westlake | Westlake | Ohio | 44145 | United States |
| BG001 | Series 1/Dose Level 2: Stereotactic Radiosurgery | Series I: Radiation will be delivered in 4 fractions: 8 Gy x 4 fractions total dose of 32 Gy. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| BG002 | Series 1/Dose Level 3: Stereotactic Radiosurgery | Series I: Radiation will be delivered in 4 fractions: 10 Gy x 4 fractions total dose of 40 Gy. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| BG003 | Series 1/Dose Level 4: Stereotactic Radiosurgery | Series I: Radiation will be delivered in 4 fractions: 12 Gy x 4 fractions total dose of 48 Gy. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| BG004 | Series 2/Dose Level 1: Stereotactic Radiosurgery | Series II: Radiation will be delivered in 3 fractions: 16 Gy x 3 fractions total dose of 48 Gy. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| BG005 | Series 2/Dose Level 2: Stereotactic Radiosurgery | Series II: Radiation will be delivered in 3 fractions: 18 Gy x 3 fractions total dose of 54 Gy. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| BG006 | Series 2/Dose Level 3: Stereotactic Radiosurgery | Series II: Radiation will be delivered in 3 fractions: 20 Gy x 3 fractions total dose of 60 Gy. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
| BG007 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Series 2: Stereotactic Radiosurgery | Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each. Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. |
|
|
| Secondary | Overall Survival | Radiographic efficacy as measured by overall (percent of participants still alive after study completion) | All participants who received treatment. | Posted | Number | percentage of participants | at 36 months from start of therapy |
|
|
|
| Secondary | Progression-free Survival | Percent of participants still alive and without tumor progression at study completion | All participants who received treatment. | Posted | Number | percentage of participants | at 36 months from start of therapy |
|
|
|
| Secondary | Freedom From Local Progression | Radiographic efficacy as measured as measured by freedom from local progression (percent of participants without local progression or local recurrence after study completion) | All participants who received treatment. | Posted | Number | percent | at 36 months from start of therapy |
|
|
|
| Secondary | Freedom to Distant Recurrence | Radiographic efficacy as measured by distant recurrance (percent of participants without distant failure after study completion) | All participants who received treatment. | Posted | Number | percent | at 36 months from start of therapy |
|
|
|
| 1 |
| 4 |
| 2 |
| 4 |
| 0 |
| 4 |
| EG001 | Series 1/Dose Level 2: Stereotactic Radiosurgery | Dose Level 2: Radiation will be delivered in 4 fractions: 8 Gy x 4 fractions: Total of 32 Gy | 0 | 6 | 1 | 6 | 1 | 6 |
| EG002 | Series 1/Dose Level 3: Stereotactic Radiosurgery | Dose Level 3: Radiation will be delivered in 4 fractions: 10 Gy x 4 fractions: Total of 40 Gy | 1 | 3 | 1 | 3 | 0 | 3 |
| EG003 | Series 1/Dose Level 4: Stereotactic Radiosurgery | Dose Level 4: Radiation will be delivered in 4 fractions: 12 Gy x 4 fractions: Total of 48 Gy | 2 | 6 | 3 | 6 | 1 | 6 |
| EG004 | Series 2/Dose Level 1: Stereotactic Radiosurgery | Dose Level I: Radiation will be delivered in 3 fractions: 16 Gy X 3 fractions: Total of 48 Gy Renal Biopsy: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance. Serum Blood Markers: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF. | 1 | 4 | 3 | 4 | 1 | 4 |
| EG005 | Series 2/Dose Level 2: Stereotactic Radiosurgery | Dose Level 2: Radiation will be delivered in 3 fractions: 18 Gy X 3 fractions: Total of 54 Gy | 0 | 4 | 1 | 4 | 3 | 4 |
| EG006 | Series 2/Dose Level 3: Stereotactic Radiosurgery | Dose Level 3: Radiation will be delivered in 3 fractions: 20 Gy X 3 fractions: Total of 6 Gy | 0 | 3 | 1 | 3 | 2 | 3 |
| Cardiac ischemia/infarction | Cardiac disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Death not associated with CTCAE term - Death NOS | General disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Death not associated with CTCAE term - Multi-organ failure | General disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Obstruction, GI - Small bowel NOS | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Necrosis, GI - Colon/cecum/appendix | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Ulcer, GI - Duodenum | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Thrombosis/thrombus/embolism | Vascular disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Infection with unknown ANC - Urinary tract NOS | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
|
| Glucose, serum-high (hyperglycemia) | Metabolism and nutrition disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Glucose, serum-low (hypoglycemia) | Metabolism and nutrition disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| CNS cerebrovascular ischemia | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Encephalopathy | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Syncope (fainting) | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Cardiac/heart | Cardiac disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Chest wall | General disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain-Head injury, head pain due to a fall. | Injury, poisoning and procedural complications | CTCAE (3.0) | Non-systematic Assessment |
|
| Renal failure | Renal and urinary disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Renal/Genitourinary Urosepsis | Renal and urinary disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Stroke | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Hypotension | Cardiac disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Fatigue (asthenia, lethargy, malaise) | General disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Rigors/chills | General disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Weight loss | General disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| SKIN OTHER: RT LEG ECZEMA | Skin and subcutaneous tissue disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Colitis | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| DIVERTICULITIS | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Hemorrhoids | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Anorexia | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Infection with unknown ANC - Urinary tract NOS | Infections and infestations | CTCAE (3.0) | Non-systematic Assessment |
|
| Creatinine | Metabolism and nutrition disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-upper | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Fracture | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Back | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Bone | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Abdomen NOS | Gastrointestinal disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Head/headache | Nervous system disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Chest wall | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Pain - Joint | Musculoskeletal and connective tissue disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Urinary retention (including neurogenic bladder) | Renal and urinary disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Incontinence, urinary | Renal and urinary disorders | CTCAE (3.0) | Non-systematic Assessment |
|
| Intra-operative injury - NERVES: Peripheral sensory NOS | Injury, poisoning and procedural complications | CTCAE (3.0) | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D013514 |
| Surgical Procedures, Operative |
| D008919 | Investigative Techniques |